United Therapeutics Corporation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
United Therapeutics Corporation (UTHR) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $45.00 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $45.00M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $46.60M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $55.60M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $64.20M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $45.00M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $46.60M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $55.60M 10-K · filed 2025-02-26 | |
| 2022-12-31 | $64.20M 10-K · filed 2024-02-21 | |
| 2021-12-31 | $73.40M 10-K · filed 2023-02-22 | |
| 2020-12-31 | $73.10M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $56.10M 10-K · filed 2021-02-24 | $56.00M 10-K · filed 2020-02-26 |
| 2018-12-31 | $57.00M 10-K · filed 2020-02-26 | $13.80M 10-K · filed 2019-02-27 |
| 2017-12-31 | $47.70M 10-K · filed 2019-02-27 | |
| 2016-12-31 | $80.10M 10-K · filed 2018-02-21 | |
| 2015-12-31 | $95.20M 10-K · filed 2017-02-22 | $95.15M 10-K · filed 2016-02-25 |
| 2014-12-31 | $86.41M 10-K · filed 2016-02-25 | |
| 2013-12-31 | $84.27M 10-K · filed 2015-02-24 | |
| 2012-12-31 | $20.24M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |